Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes

• We examine the effects of age and comorbidity in a real-life series of MDS patients.
• Both age and comorbidities exert a significant, independent impact on clinical outcome.
• The role of comorbidity in predicting outcome is best described by the MDS-CI score system.
• The impact of MDS-CI on outcome has particular relevance in lower-risk MDS patients.

BackgroundMyelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders, with very different prognosis in given individuals; age and comorbidities are emerging as relevant patient-related factors influencing clinical outcome in MDS. Our aim was to evaluate the impact of age, comorbidities and disease severity (IPSS and IPSS-R prognostic scores) in a “real-life” series of MDS patients.Methods318 patients with available assessment of comorbidities at diagnosis and consecutively registered into the Registro Ligure delle Mielodisplasie were analyzed. Comorbidities were evaluated according to HCT-CI and MDS-CI comorbidity indexes. Overall survival (OS) and the probability of death among patients who did not develop acute myeloid leukemia (NLD cumulative incidence) were analyzed.ResultsComorbidities were seen in 177 (55.7%) patients. An older age (>75 y) had a significant negative impact on OS (p = 0.008). HCT-CI was not associated with OS. MDS-CI was of prognostic significance (p = 0.001), but the association was limited to pts with IPSS or IPSS-R “lower-risk”. In multivariate analysis, MDS-CI remained an independent factor associated with OS and with an increased risk of NLD both when controlling for IPSS (p = 0.019 and p = 0.001, respectively) and for IPSS-R (p = 0.048 and p = 0.002, respectively).ConclusionsEvaluation of age and comorbidities according to a tailored tool such is MDS-CI helps to predict survival in patients with MDS and should be incorporated to current prognostic scores.